Viral and Non-Viral Vector Manufacturing : Market Developments, Size Share, Marketing Segmentations, Key Players, Future Growth Prospects and Regional Study Forecast to 2031

According to the latest research by InsightAce Analytic, The Viral and Non-Viral Vector Manufacturing Market Size is estimated to be $6.81 billion in 2023 and will grow to $28.64 billion by 2031, with a compound annual growth rate (CAGR) of 20.0 percent during the forecast period of 2024-2031.

Request For Free Sample Pages @ https://www.insightaceanalytic.com/request-sample/1263

The field of medicine has been substantially influenced by the use of vectors in advanced gene and cell therapies. The potential to treat a variety of chronic diseases and neurological disorders has been demonstrated by therapies that necessitate genetic modification. Gene therapy can potentially effectively treat and manage a wide range of disorders. Viral vectors are the most frequently used agents in gene therapy due to their exceptional ability to transport therapeutic gene replicas to host cells. Adeno-associated vectors (AAV) are the most promising among this class of vectors due to their minimal immunogenic disposition, ability to transduce dividing and non-dividing cells, and transitory nature. The development of various viral and non-viral vectors to address unmet medical requirements has been further underscored by the promising results of vector-based therapies in numerous clinical studies.

Various factors, such as the increasing prevalence of fatal diseases and the increased use of next-generation technologies in innovative medicine development primarily drive the market's expansion. It is anticipated that the market will experience significant growth in the years ahead due to the high demand for customized medications, the increasing prevalence of vector-based gene and cell treatments, the rising R&D spending for vector-based therapeutic breakthroughs, and the well-established healthcare infrastructures. The demand for therapies that necessitate genetic modification is on the rise due to the increasing prevalence of chronic and infectious diseases. Consequently, the viral and non-viral vector manufacturing market is poised for growth.
Conversely, the market's expansion in the years ahead may be impeded by the high cost of vector manufacturing, the complications associated with the large-scale production of viral and non-viral vectors, and the low transfection efficiency.

Enquiry For Before Buying @ https://www.insightaceanalytic.com/enquiry-before-buying/1263

The global viral and non-viral vector manufacturing market is expected to be led by North America in the years ahead. This is due to the rapid adoption of advanced therapy techniques and the growing scope of research and development in vector-based therapy innovations.

Key market players operating in the viral and non-viral vector manufacturing market include

• Catalent, Inc.,
• FUJIFILM Holdings Corporation,
• Evonik Industries AG,
• Exiled, Inc.,
• Entos Pharmaceuticals,
• Genevant Sciences GmbH,
• T&T Scientific Corporation,
• Moderna, Inc
• Danaher Corporation,
• Rescript Biotech Corporation,
• Lonza Group AG,
• Merck Kagan Inc.,
• Oxford Biomedical plc,
• Sartorius AG,
• Takara Bio Inc,
• Thermo Fisher Scientific Inc,
• Wuxi Optec,
• Acuities Therapeutic,
• Boehringer Ingelheim,
• CureVac N.V.

Key developments in the market:

• In May 2022, Catalent introduced its most recent UpTempo VirtuosoTM platform method for the development and CGMP production of adeno-associated viral (AAV) vectors. To significantly reduce the time from gene to clinic and facilitate a rapid clinical evaluation of the initial patient, the UpTempo Virtuoso platform standardizes and streamlines numerous time-consuming procedures in AAV manufacture.

• In December 2021, GenScript ProBio (US) unveiled China's most prominent commercial GMP plasmid manufacturing facility. The company's 6,400-square-meter manufacturing plant allows it to provide a comprehensive service for plasmids, including preclinical study (IIT), investigational new drug (IND) filing, clinical trial, and commercial manufacturing. This streamlines the innovation and development of high-quality mRNA drugs for gene and cell therapy.

• In December 2021, Oxford Biomedica plc (UK) expanded its commercial supply agreement with Novartis to produce lentiviral vectors for numerous Novartis CAR-T products.

• In October 2021, Matica Biotechnology, Inc., a contract development and manufacturing organization (CDMO) that specializes in the clinical and commercial production of cell and gene therapies, announced a joint research agreement (JRA) with Sartorius, a prominent international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will collaborate on numerous studies to optimize and expedite PAT technologies, automation software, and single-use platforms provided by Sartorius for large-scale vector production.

• In April 2021, Oxford Biomedica plc (UK) agreed to a new three-year Development & Supply Agreement ("DSA") with Boehringer Ingelheim to manufacture and supply a variety of viral vectors.

• In January 2021, Thermo Fisher Scientific Inc. and Groupe Novasep SAS (Novasep) announced that Thermo Fisher had acquired Henogen S.A., Novasep's viral vector manufacturing company in Belgium. Novasep's viral vector manufacturing division provides contract manufacturing services for vaccines and medicines to biotechnology and major biopharma customers.

Purchase this Report @ https://www.insightaceanalytic.com/buy-report/1263

Market Segments

Global Viral and Non-Viral Vector Manufacturing Market, by Vector Type
• Viral Vector
o Lentiviral Vector
o Vaccinia Viral Vector
o Adenoviral Vector
o Retroviral Vector
o Adeno-Associated Viral Vector
o Other Viral Vector
• Non-Viral Vectors
o Lipid-Based Non-Viral Vector
o Polymer-Based Non-Viral Vector
o Plasmid DNA
o Other Non-Viral Vector (Peptide-Based and Hybrid/Combination)

Global Viral and Non-Viral Vector Manufacturing Market, by Disease
• Genetic Disease
• Infectious Disease
• Cancer
• Cardiovascular Disease
• Other Diseases

Global Viral and Non-Viral Vector Manufacturing Market, by Application
• Gene Therapy
o Non-Viral Vector
o Viral Vector
• Vaccinology
o Viral Vector
o Non-Viral Vector
• Cell Therapy
o Viral Vector
o Non-Viral Vector
• Other Applications
o Viral Vector
o Non-Viral Vector

For Customized Information @ https://www.insightaceanalytic.com/customisation/1263

Global Viral and Non-Viral Vector Manufacturing Market, by Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Viral and Non-Viral Vector Manufacturing Market,
• U.S.
• Canada

Europe Viral and Non-Viral Vector Manufacturing Market,
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Viral and Non-Viral Vector Manufacturing Market,
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Viral and Non-Viral Vector Manufacturing Market,
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Viral and Non-Viral Vector Manufacturing Market,
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Get Full Report On this Market Insight @ https://www.insightaceanalytic.com/report/global-viral-and-non-viral-vector-manufacturing-market/1263

Contact Us:

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis of key market insights in a timely and cost-effective manner.

This release was published on openPR.